Brief Report: Real-World Clinical Utility of Next-Generation Sequencing of Circulating Tumor DNA for Patients With Advanced Lung Squamous Cell Carcinoma (SQUIN)
Miguel García-Pardo , Marta García de Herreros , Juan Carlos Laguna , Teresa Gorría , Yolanda Lage , Ana Gómez , Mª Eugenia Olmedo , Pilar Garrido , Víctor Manuel Albarran-Artahona , Ainara Arcocha , Cristina Teixido , Noemí Reguart , Alejandro Navarro , Edouard Auclin , Mike S Nahorski , Karen Howarth , David Planchard , Benjamin Besse , Natasha B. Leighl , Laura Mezquita
{"title":"Brief Report: Real-World Clinical Utility of Next-Generation Sequencing of Circulating Tumor DNA for Patients With Advanced Lung Squamous Cell Carcinoma (SQUIN)","authors":"Miguel García-Pardo , Marta García de Herreros , Juan Carlos Laguna , Teresa Gorría , Yolanda Lage , Ana Gómez , Mª Eugenia Olmedo , Pilar Garrido , Víctor Manuel Albarran-Artahona , Ainara Arcocha , Cristina Teixido , Noemí Reguart , Alejandro Navarro , Edouard Auclin , Mike S Nahorski , Karen Howarth , David Planchard , Benjamin Besse , Natasha B. Leighl , Laura Mezquita","doi":"10.1016/j.cllc.2025.02.007","DOIUrl":null,"url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>Plasma-based next generation sequencing (NGS) can identify clinically informative results in a meaningful proportion of patients with lung squamous cell carcinoma.</div></span></li><li><span>•</span><span><div>ESMO ESCAT tier I genomic alterations (ready for routine use; alteration-drug match associated with improved outcome in clinical trials) were found in 4% of patients.</div></span></li><li><span>•</span><span><div>Routine comprehensive molecular profiling, including plasma ctDNA NGS testing, may be considered in patients with lung squamous cell carcinoma.</div></span></li></ul></div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"26 4","pages":"Pages e300-e305.e2"},"PeriodicalIF":3.3000,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525730425000373","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
•
Plasma-based next generation sequencing (NGS) can identify clinically informative results in a meaningful proportion of patients with lung squamous cell carcinoma.
•
ESMO ESCAT tier I genomic alterations (ready for routine use; alteration-drug match associated with improved outcome in clinical trials) were found in 4% of patients.
•
Routine comprehensive molecular profiling, including plasma ctDNA NGS testing, may be considered in patients with lung squamous cell carcinoma.
期刊介绍:
Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.